OmarEtonMDFACP

PubMed

• 20 citations
  Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
  Vikas, P., Bakouny, Z., Labaki, C., Grover, P., Awosika, J., Gulati, S., Hsu, C., Alimohamed, S., Bashir, B., Berg, S., Bilen, M., Bowles, D., Castellano, C., Desai, A...> ;JAMA Oncology. 2023 Jan 1
• 24 citations
  Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
  Michael A Postow, Debra A Goldman, Alexander N Shoushtari, Allison Betof Warner, Margaret K Callahan, Parisa Momtaz, James W Smithy, Ellesa Naito, Marina K Cugliari, V...> ;Journal of Clinical Oncology. 2022 Apr 1
• 1 citations
  Combining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone.
  Emily Hsu, Omar Eton, Akshay V Patel, Richard W. Cartun, Jonathan Earle, Laila Mnayer, Jennifer Kotowitz, Peter Paul Yu> ;Journal of Drugs in Dermatology. 2021 Aug 1
• 7 citations
  Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer.
  Peter Paul Yu, Omar Eton, Louis P. Garrison> ;Journal for Immunotherapy of Cancer. 2019 Sep 3
• 11 citations
  Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports.
  Paul S White, Anita Pudusseri, Stephanie L. Lee, Omar Eton> ;Thyroid. 2017 Sep 1
• 57 citations
  Melanoma brain metastasis: overview of current management and emerging targeted therapies
  Ekokobe Fonkem, Erik J. Uhlmann, Scott R. Floyd, Anand Mahadevan, Ekkehard M. Kasper, Omar Eton, Eric T. Wong> ;Expert Review of Neurotherapeutics. 2012 Oct 1
• 61 citations
  Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
  E. Claire Dees, Jeffrey R. Infante, Roger B. Cohen, Bert H. O'Neil, Suzanne F. Jones, Margaret von Mehren, Hadi Danaee, Yih Lee, Jeffrey Ecsedy, Mark Manfredi, Katheri...> ;Cancer Chemotherapy and Pharmacology. 2011 Apr 1
• 70 citations
  Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
  Teresa Macarulla, Andrés Cervantes, Elena Elez, E. Rodríguez-Braun, José Baselga, Susana Roselló, Gemma Sala, Inma Blasco, Hadi Danaee, Yih Lee, Jeffrey Ecsedy, Vaisha...> ;Molecular Cancer Therapeutics. 2010 Oct 1
• 33 citations
  Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma
  Omar Eton, Merrick I. Ross, Mary Jo East, Paul F. Mansfield, Nicholas Papadopoulos, Julie A. Ellerhorst, Agop Y. Bedikian, Jeffrey E. Lee> ;Journal of Translational Medicine. 2010 Jan 29
• 57 citations
  A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer
  Thomas J. Lynch, David Fenton, Vera Hirsh, David Bodkin, Edward L. Middleman, Alberto Chiappori, Balazs Halmos, Reyna Favis, Hua Liu, William L. Trepicchio, Omar Eton,...> ;Journal of Thoracic Oncology. 2009 Aug 1
• 29 citations
  A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence
  Kevin B. Kim, S. S. Legha, Rene Gonzalez, Clay M. Anderson, Marcella M. Johnson, Ping Liu, Nicholas E. Papadopoulos, Omar Eton, Carl Plager, Antonio C. Buzaid, Victor ...> ;Melanoma Research. 2009 Feb 1
• 150 citations
  Phase II trial of imatinib mesylate in patients with metastatic melanoma
  K. B. Kim, Omar Eton, Darren W. Davis, Marsha L. Frazier, David J. McConkey, Abdul H. Diwan, Nicholas E. Papadopoulos, Agop Y. Bedikian, Luis H. Camacho, Merrick I. Ro...> ;British Journal of Cancer. 2008 Aug 26
• 6 citations
  Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment
  Cindy S. Hwang, Victor G. Prieto, Abdul H. Diwan, Gregory Lizée, Julie A. Ellerhorst, Suhendan Ekmekcioglu, Ping Liu, Omar Eton, Sandra A. Kinney, Elizabeth A. Grimm, ...> ;Melanoma Research. 2008 Aug 1
• Phase II study of 'hybrid' biochemotherapy for advanced melanoma.
  Papadopoulos NE, Eton O, Kim KB, Camacho LH, Hwu P, Bedikian AY> ;J. Clin. Oncol.. 2006-06-20
• A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.
  Kim KB, Legha SS, Gonzalez R, Anderson C, Papadopoulos NE, Eton O, Plager C, Roe A, Liu P, Bedikian AY> ;J. Clin. Oncol.. 2006-06-20
• 203 citations
  Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
  Ken Wyman, Michael B. Atkins, Victor G. Prieto, Omar Eton, David F. McDermott, Francie J. Hubbard, Christine Byrnes, Kathleen Sanders, Jeffrey A. Sosman> ;Cancer. 2006 May 1
• 20 citations
  Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
  Doina Ivan, Maria Niveiro, A. Hafeez Diwan, Omar Eton, Kevin B. Kim, Carol Lacey, Cipriano Gonzalez, Victor G. Prieto> ;Journal of Cutaneous Pathology. 2006 Apr 1
• 4 citations
  Chemotherapy, cytokines, and biochemotherapy for melanoma.
  Omar Eton> ;Cancer Chemotherapy and Biological Response Modifiers. 2005 Jan 1
• 14 citations
  Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
  Kevin B. Kim, Omar Eton, Mary Jo East, Cynthia Hodges, Nicholas E. Papadopoulos, Elizabeth A. Grimm, Agop Y. Bedikian> ;Cancer. 2004 Aug 1
• Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM).
  Eton O, Billings L, Kim K, Prieto V, Davis D, Frazier ML, Diwan AH, McGary E, Papadopoulos N, Bedikian AY> ;J. Clin. Oncol.. 2004-07-15
• 56 citations
  Biochemotherapy in patients with metastatic anorectal mucosal melanoma.
  Kevin B. Kim, Angela Sanguino, Cynthia Hodges, Nicholas E. Papadopoulos, Omar Eton, Luis H. Camacho, Lyle D. Broemeling, Marcella M. Johnson, Matthew T. Ballo, Merrick...> ;Cancer. 2004 Apr 1
• 48 citations
  Imatinib Mesylate Inhibits Platelet-Derived Growth Factor Receptor Phosphorylation of Melanoma Cells but Does Not Affect Tumorigenicity in Vivo
  Eric C. McGary, Amir Onn, Lisa Mills, Amy B. Heimberger, Omar Eton, Gary W. Thomas, Mikhail Shtivelband, Menashe Bar-Eli> ;The Journal of Investigative Dermatology. 2004 Feb 1
• 43 citations
  Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.
  Agop Y. Bedikian, Carl Plager, Nicholas Papadopoulos, Omar Eton, Julie A. Ellerhorst, Theresa Smith> ;Melanoma Research. 2004 Feb 1
• 80 citations
  Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array.
  Steven S. Shen, Peter Zhang, Omar Eton, Victor G. Prieto> ;Journal of Cutaneous Pathology. 2003 Oct 1
• 58 citations
  Phase II evaluation of temozolomide in metastatic choroidal melanoma
  Agop Y. Bedikian, Nicholas Papadopoulos, Carl Plager, Omar Eton, Sigrid Ring> ;Melanoma Research. 2003 Jun 1
• Join now to see all

Journal Articles

• Melanoma brain metastasis: overview of current management and emerging targeted therapies  
  Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET, Expert Rev Neurother, 1/1/2012
• Autologous tumor-derived heat-shock protein peptide complex-96 in patients with metastatic melanoma  
  Eton O, Savary CA, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Plager C, Bedikian AY, Reitsma D, Lee JE, J Transl Med, 1/1/2010
• Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics  
  Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton ..., Molecular Cancer Therapeutics, 1/1/2010
• Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors  
  Dees EC, Infante JR,Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H,4 Yih Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H, Cancer Chemotherapy & Pharmacology Cancer Chemother Pharmacol, 1/1/2010
•  
  Kim, KB, Legha, SS, Gonzalez R, Anderson C, Papadopoulos NE, Eton O, Plager C, Roe A, Liu P, Bedikian AY, Melanoma Res, 1/1/2009
• Phase II Trial of Imatinib Mesylate in Patients with Metastatic Melanoma  
  Kim KB, Eton O, Davis D, McConkey D, Frazier M, Diwan AH, McGary E, Bar-Eli M, Ng C, Papadopoulos NE, Bedikian AY, Camacho LH, Billings L, Ross MI, Mansfield PF, Gersh..., British J Cancer, 1/1/2008
• Pilot Study of High-Dose Concurrent Biochemotherapy for Advanced Melanoma  
  Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm E, Bedikian AY, Cancer, 1/1/2004
• Analysis Of Protein Tyrosine-Kinase Expression In Melanocytic Lesions By Tissue Array  
  Shen SS, Zhang PS, Eton O, Prieto VG, J Cutan Pathol, 10/1/2003
• Melanoma-Associated Retinopathy: A Harbinger of Recurrence for Cutaneous Melanoma  
  Esmaeli B, Naderi A, Ahmadi A, Wolin M, Eftekhari F, Safar S, Eton O, Int J Ophth and Visual Science, 1/1/2002
• Phase I trial of out-patient high dose subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma  
  Eton O, East M, Legha S, et al, Cancer, 1/1/2002
• Low-dose immunotherapy does not increase survival when added to chemotherapy for advanced melanoma  
  Eton O, Journal of Evidence-Based Oncology, 1/1/2002
• Phase II evaluation of bryostatin-1 in metastatic melanoma  
  Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, Smith T, Melanoma Res, 1/1/2001
• A phase II study of "decrescendo" interleukin 2 plus interferon alpha 2a in metastatic melanoma progressing after chemotherapy  
  Eton O, Buzaid A, Bedikian A, et al, Cancer, 1/1/2000
• Pilot study of intra-arterial cisplatin and intravenous vinblastine and DTIC in patients with in-transit melanoma metastases  
  Eton O, East M, Legha S, et al, Mel Res, 1/1/1999
• Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma  
  Bedikian A, Legha S, Eton O, et al, Anti-Cancer Drugs, 1/1/1999
• Prognostic factors for survival of patients treated systemically for disseminated melanoma  
  Eton O, Legha SS, Moon TE, et al, J Clin Oncol, 1/1/1998
• Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and Interleukin 2 for patients with me...  
  Legha SS, Ring S, Eton O, et al, J Clin Oncol, 1/1/1998
• DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma  
  Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, et al, Melanoma Res, 1/1/1998
• Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma  
  Yeung SJ, Eton O, Burton DW, et al, Horm Res, 1/1/1998
• Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases  
  Buzaid AC, Colome M, Bedikian A, Eton O, et al, Mel Res, 1/1/1998
• Critical Analysis of the Current AJCC Staging System for Cutaneous Melanoma and Proposal of a New Staging System  
  Buzaid AC, Ross MI, Balch CM, Soong SJ, McCarthy WH, Tinoco L, Mansfield P, Lee JE, Bedikian A, Eton O, et al, J Clin Oncol, 1/1/1997
• Phase II trial of Tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma  
  Bedikian A, Legha S, Eton O, et al, Ann Oncol, 1/1/1997
• Development and results of biochemotherapy in metastatic melanoma: The University of Texas MD Anderson Cancer Center Experience  
  Legha SS, Ring S, Eton O, et al, Cancer J Sci Am, 1/1/1997
• Evaluation of interleukin-2 administered as continuous infusion in metastatic melanoma  
  Legha SS, Gianan MA, Plager C, Eton O, Papadopoulous NEJ, Cancer, 1/1/1996
• Phase II trial of recombinant human Interleukin-2 and Interferon alpha-2a; implications for the treatment of patients with metastatic melanoma  
  Eton O, Talpaz M, Lee KH, , et al, Cancer, 1/1/1996
• Join now to see all

Abstracts/Posters

• Phase I Evaluation of MLN8237, a Novel Aurora A Kinase Inhibitor
  Dees EC, Infante J, Burris H, O’Neil B, Murphy P, Eton O, Lee Y, Pappas J, Ecsedy JA, Cohen RB, Chemotherapy Foundation Symposium XXVI, 11/4/2008
• Phase I and Pharmacokinetic Study of MLN8054, a Selective Inhibitor of Aurora A Kinase
  Dees EC, Infante JR, Cohen RB, O’Neil BH, Burris H, von Mehren M, Gray G, Galvin K, Manfredi M, Eton O, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• Phase I Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MLN8237, a Selective Aurora A Kinase Inhibitor, in the United States
  Infante J, Dees EC, Cohen RB, Burris H, O’Neil B, Murphy P, Lee Y, Pappas J, Ecsedy JA, Eton O, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• MLN8237, an Oral Selective Aurora A Kinase Inhibitor: Initial Results of Dose-Finding Pharmacokinetic-Pharmacodynamic Phase I Study
  Tabernero Caturla J, Cervantes A, Elez E, Macarulla T, Rosello S, Rodríguez-Braun E, Stringer B, Shinde V, Danaee H, Eton O, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• Phase I assessment of mechanistic pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase
  Chakravarty A, Shinde V, Bowman D, Galvin K, Silverman L, Stringer B, Danaee H, Eton O, Manfredi M, Ecsedy J, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• Dosing Strategies for MLN8054, a Selective Aurora A Kinase Inhibitor, Based on Pharmacokinetic Modeling and Simulations
  Lee Y, Eton O, Pappas J, Chen S, Paton M, EORTC-NCI-AACR 2008 Conference, 10/21/2008
• Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase
  S. F. Jones, R. B. Cohen, E. C. Dees, Y. Lee, Eton O, J. A. Papas, M. R. Cooper, K. M. Galvin, H. A. Burris, Proc Am Soc Clin Oncol, 1/1/2007
• Phase II study of "hybrid" biochemotherapy for advanced melanoma
  Papadopoulos NE, Eton O, Kim KB, Camacho LH, Hwu P, Bedikian AY, Proc Am Soc Clin Oncol, 1/1/2006
• Phase II Trial of Imatinib Mesylate (STI-571) in Metastatic Melanoma (MM)
  Eton O, Billings L, Kim K, Prieto V, Davis D, Frazier ML, Diwan AH, McGary E, Papadopoulos N, Bedikian AY, Proc Am Soc Clin Oncol, 1/1/2004
• Phase II evaluation of short IV infusion of paclitaxel in metastatic melanomBedikian AY, Papadopoulos N, Plager C, Eton O, Ellerhorst J, Smith T
  Bedikian AY, Papadopoulos N, Plager C, Eton O, Ellerhorst J, Smith T, Proc Am Soc Clin Oncol, 1/1/2002
• Pilot study of high dose concurrent biochemotherapy for advanced melanoma
  Kim KB, Eton O, East MJ, Plager C, Papadopoulos NE, Hodges C, Rohl C, Grimm EA, Bedikian AY, Proc Am Soc Clin Oncol, 1/1/2002
• Clinical pharmacology studies of rhIL-2: Comparison of intravenous (IV) and subcutaneous (SC) routes
  Rosenblum MG, Zhang W, Eton O, Proc Am Assoc Cancer Res, 1/1/2000
• Phase I trial of out-patient high dose subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma
  Eton O, East M, Legha S, Bedikian A, Papadopoulos N, Buzaid A, Rosenblum MG, Benjamin RS, Proc Am Soc Clin Oncol, 1/1/1999
• Psychosocial factors predict adjustment in cancer patients
  Cohen L, Eton O, Moor C, Amato R, East M, Proc SBM, 1/1/1999
• The nurse clinician’s role in management of patients receiving autologous UVB-irradiated (UVR) whole melanoma cell vaccine
  Gianan M, Eton O, Kharkhevitch D, Proc ONS, 1/1/1998
• In vitro DNA damage as predictor of response to biochemotherapy in melanoma
  Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha S, Benjamin R, Proc Amer Assoc Cancer Res, 1/1/1997
• In vitro DNA damage as predictor of response to biochemotherapy
  Buzaid AC, Ali-Osman FA, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha S, Benjamin R, Proc Amer Assoc Cancer Res, 1/1/1997
• Phase II trial of tirapazamine (escalated dose) plus cisplatin in patients with advanced melanoma
  Bedikian AY, Legha SS, Buzaid AC, Eton O, Papadopoulos N, McIntyre S, Montogomery D, von Roemelling R, Proc Am Soc Clin Oncol, 1/1/1997
• Results of biochemotherapy in the treatment of advanced melanoma, The M. D. Anderson Cancer Center Experience
  Bedikian AY, Legha SS, Buzaid AC, Eton O, Papadopoulos N, Plager C, Ross M, Lee J, Mansfield P, Benjamin R, Mel Res, 1/1/1997
• Biochemotherapy studies in the treatment of advanced melanoma
  Legha SS, Bedikian A, Plager C, Eton O, Buzaid A, Papadopoulos N, Ross M, Mel Res, 1/1/1997
• Phase II trial of tirapazamine plus cisplatin in patients with advanced melanoma. Proc Am Soc Clin Oncol 15:434, 1996.
  Bedikian AY, Legha SS, Buzaid AC, Eton O, Papadopoulos N, Coates S, Simmons T, von Roemeling R, Proc Am Soc Clin Oncol, 1/1/1996
• Neoadjuvant biochemotherapy in melanoma patients (pts) with local regional metastases (LRM)
  Buzaid AC, Legha S, Bedikian A, Eton O, Papadopoulos N, Plager C, Ross M, Lee J, Mansfield P, Strom E, Ring S, Rice J, Colome M, Benjamin R, Proc Am Soc Clin Oncol, 1/1/1996
• A pilot study of interferon alfa-2b and cis-platin, velban and DTIC (CVD) in metastatic melanoma
  Plager C, Papadopoulos NE, Gianan MA, Bedikian AY, Buzaid AC, Eton O, Legha SS, Benjamin RS, Proc Am Soc Clin Oncol, 1/1/1996
• Phase II trial of Tirapazamine (TIRA) plus Cisplatin in patients (pts) with advanced malignant melanoma
  Bedikian A, Legha S, Buzaid A, Eton O, Papadopoulos NE, von Roemeling R, Sixth World Congress on Cancers of the Skin, 9/16/1995
• Combined biochemotherapy in the treatment of advanced melanoma
  Legha SS, Ring S, Bedikian AY, Plager C, Eton O, Buzaid A, Papadopoulos N, Proc 38th Annual Clinical Conference on Advanced in the Biology and Clinical Management of Melanoma, 1/1/1995
• Join now to see all

Lectures

• Payment Reform 
  Best of ASCO, Boston, MA - 8/8/2014
• Preparing for a career in clinical translational research 
  1/1/2013
• Grand Rounds, Board Reviews... 
  Various locations - 1/1/2000